Clinical Trials Logo

Filter by:
NCT ID: NCT03496675 Active, not recruiting - Depression Clinical Trials

Music Interventions for Dementia and Depression in Elderly Care

MIDDEL
Start date: July 18, 2018
Phase: N/A
Study type: Interventional

This study evaluates the effectiveness of two music-based approaches - group music therapy and recreational choir singing - for reducing depression symptoms in people living with dementia. It also examines mechanisms and heterogeneity of treatment effects.

NCT ID: NCT03485677 Active, not recruiting - Clinical trials for Gaucher's Disease Type III

Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

ELIKIDS
Start date: April 11, 2018
Phase: Phase 3
Study type: Interventional

Primary Objective: Evaluate the safety and pharmacokinetics of eliglustat in pediatric patients (≥2 to <18 years old). Secondary Objective: Evaluate the efficacy of eliglustat and quality of life in pediatric patients (≥2 to <18 years old).

NCT ID: NCT03484559 Active, not recruiting - Cardiac Arrest Clinical Trials

The Assessment of Survival After In-hospital Cardiac Arrest for 2 Years in Tertiary Hospital

IHCA
Start date: February 2, 2018
Phase:
Study type: Observational

Define the frequency and survival pattern of cardiac arrests in relation to the hospital day of event and etiology of arrest.

NCT ID: NCT03473743 Active, not recruiting - Clinical trials for Urothelial Carcinoma

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Start date: April 5, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to: (a) characterize the safety and tolerability of and to identify the recommended Phase 2 dose (RP2D) and schedule for erdafitinib in combination with cetrelimab, and for erdafitinib in combination with cetrelimab and platinum (cisplatin and carboplatin) chemotherapy and; (b) to evaluate the safety and clinical activity of erdafitinib alone and in combination with cetrelimab in cisplatin-ineligible participants with metastatic or locally advanced urothelial cancer (UC) with select fibroblast growth factor receptor (FGFR) gene alterations and no prior systemic therapy for metastatic disease.

NCT ID: NCT03466411 Active, not recruiting - Crohn's Disease Clinical Trials

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

GALAXI
Start date: April 13, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

NCT ID: NCT03462719 Active, not recruiting - Clinical trials for Leukemia, Lymphocytic, Chronic, B-Cell

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

GLOW
Start date: April 17, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).

NCT ID: NCT03456076 Active, not recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Start date: August 16, 2018
Phase: Phase 3
Study type: Interventional

This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting. Participants in the experimental arm will receive alectinib at 600 mg orally twice daily (BID) taken with food for 24 months. Participants in the control arm will receive one of the protocol specified platinum based chemotherapy regimens for 4 cycles. Following treatment completion, participants will be followed up for their disease until disease recurrence. At the time of disease recurrence, participants will enter a survival follow-up until death, withdrawal of consent or study closure, whichever occurs earlier.

NCT ID: NCT03449290 Active, not recruiting - Kinesio Taping Clinical Trials

The Short-term Effects of Trunk Kinesio Taping on Trunk Muscle Endurance and Postural Stability in Healthy Young Adults

Start date: February 15, 2018
Phase: N/A
Study type: Interventional

This study aimed to investigate the short-term effects of trunk kinesio taping on trunk muscle endurance and postural stability in healthy young adults.

NCT ID: NCT03443778 Active, not recruiting - Tonsillectomy Clinical Trials

Dexamethasone-bupivacaine Versus Bupivacaine for Tonsillectomy Pain.

Start date: December 15, 2017
Phase: Phase 4
Study type: Interventional

Investigators compared in this study peritonsillar infiltration of bupivacaine %0.5 (n=40 participants) versus bupivacaine % 0.5 and dexamethasone (number 40participants ) before surgery for reduce posttonsillectomy pain.And control group (n= 40participants) participants received peritonsillar Nacl 0,9% .

NCT ID: NCT03440372 Active, not recruiting - Crohn Disease Clinical Trials

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Start date: February 27, 2018
Phase: Phase 3
Study type: Interventional

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.